VU University Medical Center

Ring Therapeutics Announces Appointment of Industry Veteran Christopher Wright, M.D., Ph.D. as Chief Medical Officer, Head of Translational Research

Retrieved on: 
Monday, January 30, 2023
Translational research, MBA, Alkermes, Hospital, Harvard University, Harvard Medical School, VU University Medical Center, Drug development, Flagship Pioneering, Patient, MMSc, Vertex Pharmaceuticals, Ironwood Pharmaceuticals, Senior, Tissue, Associate, Toxicity, Ring, Neurology, Therapy, Pharmaceutical industry, Brigham

Dr. Wright brings over two decades of clinical, medical research and drug development experience to the team.

Key Points: 
  • Dr. Wright brings over two decades of clinical, medical research and drug development experience to the team.
  • “We welcome the addition of Chris to the team as Ring’s first Chief Medical Officer and Head of Translational Research,” said Tuyen Ong, M.D., MBA, Chief Executive Officer at Ring Therapeutics and CEO-Partner at Flagship Pioneering.
  • Previously, Dr. Wright served as Chief Medical Officer at Cyclerion, and Senior Vice President/Chief Development Officer at Ironwood Pharmaceuticals.
  • He currently serves on the Board of Directors at Alkermes plc, and as Scientific Advisor at Cyclerion Therapeutics, Inc.

Freya Pharma Solutions Announces Appointment of Dr. Jan van der Mooren as Chief Medical Officer, to guide its pivotal phase 3 clinical trial with Lybrido against FSIAD

Retrieved on: 
Tuesday, April 12, 2022
VU University Medical Center, Female, American, Plasma, Phases of clinical research, Lists of diseases, Obstetrics, Research, Danone, Declaration of Helsinki, Clinical trial, No, DSM-5, Testosterone, Clinical research, CMO, PDE, American Psychiatric Association, Doctor of Philosophy, Person, Woman, Human sexual response cycle, Sexual dysfunction, EU, Senior, Saint Luke's Home for Destitute and Aged Women, Grammatical mood, Arousal, Knowledge, Safety, Master of Science, GCP, Good, Associate professor, EMA, Union, Communication, Lubrication, Department, GMP, Education, Science, Excellence, Patient, Pharmaceutical industry, Birth control, Freyja, Buspirone/testosterone, Nutricia, Epidemiology

AMSTERDAM, April 12, 2022 /PRNewswire/ -- Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD), today announced the appointment of Jan van der Mooren MD, PhD, MSc (picture below) as Chief Medical Officer as per April 2022. Dr. Van der Mooren is a medical doctor with additional education in Gynaecological Endocrinology and Epidemiology. He has been involved in clinical research since 1990. Prior to his appointment he was Senior Director of the Danone Nutricia Research Center in Utrecht, the Netherlands. Jan will be in the lead of Freya's steering committee overseeing the upcoming phase 3 study of Lybrido to confirm its efficacy in women suffering from FSIAD.

Key Points: 
  • Dr. Van der Mooren is a medical doctor with additional education in Gynaecological Endocrinology and Epidemiology.
  • Jan will be in the lead of Freya's steering committee overseeing the upcoming phase 3 study of Lybrido to confirm its efficacy in women suffering from FSIAD.
  • Dr. Van der Mooren brings to Freya three decades of life sciences experience in clinical development and medical affairs in nutrition, epidemiology, obstetrics and gynaecology.
  • Freya Pharma Solutions plans to conduct the pivotal phase 3 clinical trial to confirm the efficacy of Lybrido in women suffering from FSIAD.

Freya Pharma Solutions Announces Appointment of Dr. Jan van der Mooren as Chief Medical Officer, to guide its pivotal phase 3 clinical trial with Lybrido against FSIAD

Retrieved on: 
Tuesday, April 12, 2022
VU University Medical Center, Female, American, Plasma, Phases of clinical research, Lists of diseases, Obstetrics, Research, Danone, Declaration of Helsinki, Clinical trial, No, DSM-5, Testosterone, Clinical research, CMO, PDE, American Psychiatric Association, Doctor of Philosophy, Person, Woman, Human sexual response cycle, Sexual dysfunction, EU, Senior, Saint Luke's Home for Destitute and Aged Women, Grammatical mood, Arousal, Knowledge, Safety, Master of Science, GCP, Good, Associate professor, EMA, Union, Communication, Lubrication, Department, GMP, Education, Science, Excellence, Patient, Pharmaceutical industry, Birth control, Freyja, Buspirone/testosterone, Nutricia, Epidemiology

AMSTERDAM, April 12, 2022 /PRNewswire/ -- Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD), today announced the appointment of Jan van der Mooren MD, PhD, MSc (picture below) as Chief Medical Officer as per April 2022. Dr. Van der Mooren is a medical doctor with additional education in Gynaecological Endocrinology and Epidemiology. He has been involved in clinical research since 1990. Prior to his appointment he was Senior Director of the Danone Nutricia Research Center in Utrecht, the Netherlands. Jan will be in the lead of Freya's steering committee overseeing the upcoming phase 3 study of Lybrido to confirm its efficacy in women suffering from FSIAD.

Key Points: 
  • Dr. Van der Mooren is a medical doctor with additional education in Gynaecological Endocrinology and Epidemiology.
  • Jan will be in the lead of Freya's steering committee overseeing the upcoming phase 3 study of Lybrido to confirm its efficacy in women suffering from FSIAD.
  • Dr. Van der Mooren brings to Freya three decades of life sciences experience in clinical development and medical affairs in nutrition, epidemiology, obstetrics and gynaecology.
  • Freya Pharma Solutions plans to conduct the pivotal phase 3 clinical trial to confirm the efficacy of Lybrido in women suffering from FSIAD.

Michiel Soeting joins the VEON Board as a non-executive Director

Retrieved on: 
Wednesday, March 16, 2022
Chartered accountant, MBA, EMEA, United Kingdom, VEON, KPMG, VU University Medical Center, Forward-looking statement, Risk management, NASDAQ, Euronext Amsterdam, Board, Michiel, Audit, Georgia Southern University, Nature, APAC, Management, Economics

AMSTERDAM, March 16, 2022 /PRNewswire/ --VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a leading global provider of connectivity and internet services, today announced that Michiel Soeting, former global lead partner from KPMG, has joined the VEON Board as a non-executive director and Chairman of the Audit & Risk Committee effective 16 March 2022.

Key Points: 
  • AMSTERDAM, March 16, 2022 /PRNewswire/ --VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a leading global provider of connectivity and internet services, today announced that Michiel Soeting, former global lead partner from KPMG, has joined the VEON Board as a non-executive director and Chairman of the Audit & Risk Committee effective 16 March 2022.
  • VEON has a diverse investor base with no controlling shareholder, a majority of independent directors and an international management team.
  • Michiel graduated from Vrije University in the Netherlands as a Chartered Accountant where he completed his Doctoral in Economics.
  • Gennady Gazin, Chairman of the Board, said: "We welcome Michiel as an independent director to our Board, and we look forward to working with him.

Mr. Jeroen Tas Joins Zylorion as a Strategic Advisor and Observer to the Board of Directors

Retrieved on: 
Thursday, January 6, 2022
AB, VU University Medical Center, EDS, NASSCOM, Anxiety, Pacific City Bank, Internet, Director, Research, Company, Depression, NYSE, The Advisory Board Company, Intention, RTO, TRD, MDD, Phrase, Computer science, Information technology, PTSD, History, HP, Lists of diseases, Legislation, Board, News, Mental health, Technology, Post-traumatic stress disorder, Board of directors, European, COO, Multimedia, Pharmaceutical industry, Online shopping, Management, Michichi

Mr. Tas is the 2004 winner of the E&Y Entrepreneur of the Year award in the Information Technology category for the New York region.

Key Points: 
  • Mr. Tas is the 2004 winner of the E&Y Entrepreneur of the Year award in the Information Technology category for the New York region.
  • Mr. Tas is a native of the Netherlands and holds a Master's in Computer Science and Business Administration from the Vrije University, Amsterdam.
  • In his role as a Strategic Advisor and Board Observer, Mr. Tas will provide strategic guidance and advise the development and delivery of the Company's clinical, and technology enabled therapy programs.
  • Mr. Tas will also be acting as a non-voting observer to the Board of Directors.

Preclinical tasquinimod data presented at ASH 2021 available on Active Biotech’s website

Retrieved on: 
Wednesday, December 15, 2021
Therapy, Teaching hospital, VU University Medical Center, Lymphatic system, MDS, Laquinimod, Myelodysplastic syndrome, Osteoblast, NASDAQ, 2021 Essex County Council election, Bone marrow suppression, CEO, Biotechnology, CET, Patient, Disease, CFO, Multiple myeloma, Vrije Universiteit Amsterdam, ASH, Brussels, Partnership, Active, EST, Naptumomab estafenatox, ACTI, Pharmaceutical industry, Medical device, Vitro

Lund, December 15, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on its candidate drug tasquinimod, a small molecule immunomodulator, are now available on the companys website.

Key Points: 
  • Lund, December 15, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on its candidate drug tasquinimod, a small molecule immunomodulator, are now available on the companys website.
  • The data were presented at two poster presentations at the 63rd ASH Annual Meeting & Exposition in Atlanta, Georgia.
  • The results presented are part of Active Biotechs program to address the unmet medical needs to treat hematological malignances, including multiple myeloma.
  • The first poster is from our collaboration with an academic group at Vrije Universiteit, Brussel, to further study tasquinimod in the preclinical setting of multiple myeloma.

Idera Pharmaceuticals Announces Tilsotolimod Updates

Retrieved on: 
Tuesday, December 14, 2021
AbbVie, U.S. Securities and Exchange Commission, Neoplasm, Food, SD, Intellectual property, Company, COVID-19 CPI, Clinical trial, VUMC, Drug Quality and Security Act, Securities Exchange Act of 1934, Nasdaq, Idera, Inc., COVID-19, RECIST, Acquisition, Securities Act of 1933, Immunotherapy, Intention, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Antigen presentation, Patient, VU University Medical Center, Disease, Security (finance), Immune system, Overalls, Flow cytometry, Coronavirus, Nivolumab, GLOBE, PD, TLR9, Ipilimumab, B cell, Partial-response maximum-likelihood, Pharmaceutical industry, Medical imaging

EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera, the Company, we, us, and our) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its synthetic Toll-like receptor 9 agonist.

Key Points: 
  • EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera, the Company, we, us, and our) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its synthetic Toll-like receptor 9 agonist.
  • AbbVie is solely responsible for the conduct of the study, with Idera contributing tilsotolimod supply.
  • These data are consistent with previously reported translational data relating to tilsotolimod in other pre-clinical and clinical settings.
  • Intratumoral injection of tilsotolimod has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive (T cells) immune activation.

New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)

Retrieved on: 
Thursday, November 4, 2021
Teaching hospital, Naptumomab estafenatox, CFO, 2021 Essex County Council election, Biotechnology, Active, III, MDS, Abstract (summary), Bone marrow suppression, Partnership, Patient, CET, NASDAQ, ACTI, Laquinimod, Multiple myeloma, ASH, Central European, Lymphatic system, VU University Medical Center, CEO, EU, Therapy, Osteoblast, Animal, Pharmaceutical industry, Medical device

Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo.

Key Points: 
  • Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo.
  • Targeting the Inflammatory Niche in MDS By Tasquinimod Restores Hematopoietic Support and Suppresses Immune-Checkpoint Expression in Vitro Poster session 636.
  • Myelodysplastic Syndromes Basic and Translational: Poster II., Dec 12, 2021, 6.00-8.00 p.m. M. Wobus et al., University Hospital Dresden, Germany.
  • Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor's ability to grow and metastasize.

Aviceda Therapeutics Announces Additional World-Class Members to its Scientific Advisory Board

Retrieved on: 
Monday, September 20, 2021
Technology, Research, Infectious Diseases, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Therapy, VU University Medical Center, JAK3, List of pathologists, KNAW, Dendrite, ERC, Cell, Royal Netherlands Academy of Arts and Sciences, Harvard Medical School, SCID, Aviceda, Inflammation, Pathology, Coronavirus Scientific Advisory Board (Turkey), Cell biology, IP, Immune system, Cancer research, Science, Amgen, JEM, HIV, COO, GA, UCLA, FIH, CSO, Molecular biology, Ghost, DNA repair, DNA, Geographic atrophy, Government, Autosome, Cancer Research UK, Doctor of Philosophy, College, Government of Northern Ireland, Society, Dendritic cell, College of American Pathologists, DNAR, II, NWO, Cancer, CLIA, Patient, Biomarker, Biology, CLEP, McClay, NIH, PNAS, Pharmaceutical industry, Vaccine, Medicine

Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.

Key Points: 
  • Aviceda Therapeutics, an IND-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing additional members of its Scientific Advisory Board who will help shape ongoing research and development efforts.
  • The new additional Aviceda Scientific Advisory Board members includes:
    Aviceda is honored and privileged to add new world-class scientists and renowned researchers to join our efforts in developing the next generation of glyco-immune therapeutics for the treatment of immune-dysfunction conditions, said Mohamed A. Genead, MD, Co-Founder & President of Aviceda Therapeutics.
  • She published more than 280 scientific papers in well recognized journals (Cell, Nature, Nature Immunology, PNAS, and JEM) and supervised 29 PhD students.
  • The Aviceda team is already building on the foundational work in the emerging field of glycobiology to develop potential therapeutics and interventional strategies.

ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002

Cloud, Badminton Association of India, Company, Optimism, Neurodegeneration, VU University Medical Center, ALS, Ageing, IBC, Amyloid, Neuroprotection, Trial of the century, Communication, Immune system, Family, Maintenance, NIA, National Institute on Aging, Weizmann Institute of Science, Disease, Research, Antibody, ALS Association, National, Neuron, DRS, Biology, Arrest, Cognition, Clinical trial, Synapse, Safety, Government budget balance, Patient, Principal, NIH, Association, Israel Innovation Authority, Brain, National Institute, Vaccine, Pharmaceutical industry

The phase 1b safety and proof-of-mechanism study of IBC-Ab002 in patients with mild Alzheimers disease is expected to start in the first half of 2022 in the UK, the Netherlands and in Israel.

Key Points: 
  • The phase 1b safety and proof-of-mechanism study of IBC-Ab002 in patients with mild Alzheimers disease is expected to start in the first half of 2022 in the UK, the Netherlands and in Israel.
  • In addition to the NIA funding, the study will be funded in part by a grant received from the Alzheimers Association under the 2020 Part the Cloud + Bill Gates Partnership Grant Program.
  • Dr. Jesse Cedarbaum , IBCs Chief Medical Officer, said: Aging is the major risk factor for the development of Alzheimers disease.
  • IBC plans to start its phase 1b clinical trial in the first half of 2022 in patients with early Alzheimers disease.